{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:23:16Z","timestamp":1783045396456,"version":"3.54.6"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before the first vaccination, and 1\u20133 and 4\u20136\u00a0months after the second vaccination. The primary endpoint was the seroconversion rate measured 1\u20133\u00a0months after the second vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 590 patients and 183 healthy hospital staff were analyzed. At 1\u20133\u00a0months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU\/mL) in 96.1% (567\/590) of the patients with cancer and 100% (183\/183) of the healthy controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0024). At 4\u20136\u00a0months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU\/ml for S-IgG) in 93.1% (461\/495) of the patients with cancer and 100% (170\/170) of the healthy controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Old age, being male, and low lymphocyte count were related to low SARS-CoV-2 S-IgG levels 1\u20133\u00a0months after the second vaccination among patients, while body mass index, smoking history, and serum albumin level were not. Patients undergoing platinum combination therapy and alkylating agent among cytotoxic drugs, and PARP inhibitor, mTOR inhibitor, and BCR-ABL inhibitor exhibited a low S-IgG antibody concentration compared to the no treatment group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>COVID-19 vaccine immunogenicity was reduced among patients with cancer, especially under several treatment regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-024-02470-x","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T03:02:58Z","timestamp":1708484578000},"page":"386-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2127-3601","authenticated-orcid":false,"given":"Yuki","family":"Katsuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Yagishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Nakahama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Yanagida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Irino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"issue":"2","key":"2470_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1158\/2159-8290.CD-20-1817","volume":"11","author":"A Ribas","year":"2021","unstructured":"Ribas A, Sengupta R, Locke T et al (2021) Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov 11(2):233\u2013236","journal-title":"Cancer Discov"},{"key":"2470_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1200\/GO.20.00225","volume":"6","author":"VG Giannakoulis","year":"2020","unstructured":"Giannakoulis VG, Papoutsi E, Siempos II (2020) Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO Glob Oncol 6:799\u2013808","journal-title":"JCO Glob Oncol"},{"issue":"8","key":"2470_CR3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2021.2159","volume":"7","author":"S Yazaki","year":"2021","unstructured":"Yazaki S, Yoshida T, Kojima Y et al (2021) Difference in SARS-CoV-2 antibody status between patients with cancer and health care workers during the COVID-19 pandemic in Japan. JAMA Oncol 7(8):1141\u20131148","journal-title":"JAMA Oncol"},{"key":"2470_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2021.110793","volume":"195","author":"L Vimercati","year":"2021","unstructured":"Vimercati L, Stefanizzi P, De Maria L et al (2021) Large-scale IgM and IgG SARS-CoV-2 serological screening among healthcare workers with a low infection prevalence based on nasopharyngeal swab tests in an Italian university hospital: perspectives for public health. Environ Res 195:110793","journal-title":"Environ Res"},{"key":"2470_CR5","volume-title":"Coronavirus disease (COVID-19) dashboard 2021","author":"WHO","year":"2021","unstructured":"WHO (2021) Coronavirus disease (COVID-19) dashboard 2021. WHO, Geneva"},{"key":"2470_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101143","author":"FP Bianchi","year":"2021","unstructured":"Bianchi FP, Tafuri S, Migliore G et al (2021) BNT162b2 mRNA COVID-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection and symptomatic disease in five-month follow-up: a retrospective cohort study. Vaccines. https:\/\/doi.org\/10.3390\/vaccines9101143","journal-title":"Vaccines"},{"issue":"3","key":"2470_CR7","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1016\/S2214-109X(21)00593-3","volume":"10","author":"EPK Parker","year":"2022","unstructured":"Parker EPK, Desai S, Marti M et al (2022) Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Lancet Glob Health 10(3):e326\u2013e328","journal-title":"Lancet Glob Health"},{"issue":"12","key":"2470_CR8","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","volume":"22","author":"SF Oosting","year":"2021","unstructured":"Oosting SF, van der Veldt AAM, GeurtsvanKessel CH et al (2021) mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol 22(12):1681\u20131691","journal-title":"Lancet Oncol"},{"key":"2470_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101608","volume":"52","author":"N Teeyapun","year":"2022","unstructured":"Teeyapun N, Luangdilok S, Pakvisal N et al (2022) Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: a prospective, multicenter observational study. EClinicalMedicine 52:101608","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2470_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7883\/yoken.JJID.2022.093","volume":"76","author":"S Tanaka","year":"2023","unstructured":"Tanaka S, Umezawa J, Yamaji T et al (2023) SARS-CoV-2 antibody response to symptoms indicative of COVID-19 in a non-infected population in Japan: a cross-sectional study. Jpn J Infect Dis 76(1):46\u201354","journal-title":"Jpn J Infect Dis"},{"issue":"1","key":"2470_CR11","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1038\/s41598-021-84387-3","volume":"11","author":"K Noda","year":"2021","unstructured":"Noda K, Matsuda K, Yagishita S et al (2021) A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci Rep 11(1):5198","journal-title":"Sci Rep"},{"issue":"1","key":"2470_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cell.2020.09.005","volume":"183","author":"L Au","year":"2020","unstructured":"Au L, Boos LA, Swerdlow A et al (2020) Cancer, COVID-19, and antiviral immunity: the CAPTURE study. Cell 183(1):4\u201310","journal-title":"Cell"},{"key":"2470_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejca.2021.09.030","volume":"159","author":"T Buttiron Webber","year":"2021","unstructured":"Buttiron Webber T, Provinciali N, Musso M et al (2021) Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. Eur J Cancer 159:105\u2013112","journal-title":"Eur J Cancer"},{"issue":"24","key":"2470_CR14","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-21-2439","volume":"27","author":"V Di Noia","year":"2021","unstructured":"Di Noia V, Pimpinelli F, Renna D et al (2021) Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution. Clin Cancer Res 27(24):6815\u20136823","journal-title":"Clin Cancer Res"},{"key":"2470_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101148","author":"M Liontos","year":"2021","unstructured":"Liontos M, Terpos E, Markellos C et al (2021) Immunological response to COVID-19 vaccination in ovarian cancer patients receiving PARP inhibitors. Vaccines. https:\/\/doi.org\/10.3390\/vaccines9101148","journal-title":"Vaccines"},{"issue":"2","key":"2470_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.annonc.2021.10.014","volume":"33","author":"C Corti","year":"2022","unstructured":"Corti C, Antonarelli G, Scott\u00e9 F et al (2022) Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review. Ann Oncol 33(2):158\u2013168","journal-title":"Ann Oncol"},{"issue":"9","key":"2470_CR17","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S2213-2600(21)00266-6","volume":"9","author":"D Bernal-Bello","year":"2021","unstructured":"Bernal-Bello D, Morales-Ortega A, Isabel Farf\u00e1n-Sedano A et al (2021) Imatinib in COVID-19: hope and caution. Lancet Respir Med 9(9):938\u2013939","journal-title":"Lancet Respir Med"},{"key":"2470_CR18","unstructured":"World Health Organization. https:\/\/www.who.int\/countries\/jpn\/"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02470-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02470-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02470-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T04:09:11Z","timestamp":1711339751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02470-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2470"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02470-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3605676\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"12 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report the following conflicts of interest: YT Grants or contracts from AMGEN, AstraZeneca, Takeda, Daiichi Sankyo, Ono, MSD, Abbvie, Novartis, Chugai, Merck, Blueprint and BMS, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Takeda, Daiichi Sankyo, Boehringer-Ingelheim, TAIHO, Chugai, Novartis, Lilly, MSD, Ono, and BMS, Participation on a Data Safety Monitoring Board or Advisory Board from AstraZeneca, Novartis, AMGEN, MSD, and Chugai. AT Honaria from Lilly, Ono, Chugai pharma, Taiho, Takeda, Research funding from MSD, AstraZeneca, Amgen, Eisai, BMS, ONO. KY Advisory Board from Novartis, Eisai, AstraZeneca, Chugai, Takeda, Genmab, OncXerna. Research support (to institution) from MSD, Daiichi-Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, Haihe. Honorarim for lecture from Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, MSD, Boehringer Ingelheim\u3001Ono, Daiichi-Sankyo, PDR pharma, Bayel. AO Grants or contracts from Ono and Daiichi Sankyo. Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Ono and Servier. AH Grants or contracts from Sysmex. YI and MY salaried employee of Sysmex Corporation. NY Research grants from Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Pharma, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, TORAY, KAKEN, AstraZeneca, Cimic. Advisory role of Eisai, Takeda, Otsuka, Boehringer Ingelheim, Cimic, Chugai, Healios. Speakers bureaus from ONO, Chugai, Daiichi-Sankyo, Eisai. All other authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}